Drug Profile
Linrodostat - Bristol-Myers Squibb
Alternative Names: BMS-986205; BMS-986205-04; F00-1287; Linrodostat mesylate; ONO-7701Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Ono Pharmaceutical
- Class Acetamides; Aniline compounds; Antineoplastics; Cyclohexanes; Quinolines; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bladder cancer; Head and neck cancer
- Phase II Endometrial cancer; Gastric cancer; Malignant melanoma
- Phase I/II Cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
- No development reported Glioblastoma
Most Recent Events
- 03 May 2023 Bristol-Myers Squibb terminates phase II CheckMate 9UT trial in Bladder cancer (Monotherapy, Late-stage disease, Metastatic disease) in Argentina, Mexico, USA, Brazil, Canada, Chile, China, France, Hong Kong, Italy, the Netherlands, Russia, Spain, United Kingdom due to insufficient enrollment (PO) (NCT03519256) (EudraCT2017-003581-27)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Newly diagnosed) in USA (PO)
- 10 Sep 2022 Efficacy data from early phase-I and phase-II trials in Head and Neck cancer presented at the 47th European Society for Medical Oncology Congress ,